Literature DB >> 11244153

Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale.

A Akdemir1, M H Türkçapar, S D Orsel, N Demirergi, I Dag, M H Ozbay.   

Abstract

The aim of the study was to examine the reliability and validity of the Turkish version of the Hamilton Depression Rating Scale (HDRS). Ninety-four patients with major depression/depressive mood disorders and 40 healthy controls participated in the study. The severity of depression was assessed with the HDRS, Beck Depression Inventory (BDI), and Clinical Global Impression score (CGI). The test-retest reliability coefficient of the HDRS was based on a 5-day interval was.85, with a Cronbach alpha coefficient of.75 and a split-half reliability coefficient of.76. Interrater reliability coefficients based on the independent ratings of four assessors were between.87 and.98. The correlation between the HDRS and BDI scores was.48, and between the HDRS and CGI it was.56. Principal Components Analysis yielded six factors. The correlation (-.13) between the control and patient groups indicates that the HDRS assesses depression very well. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11244153     DOI: 10.1053/comp.2001.19756

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  27 in total

1.  Assessment of quality of life and depression in spouses of patients with ankylosing spondylitis.

Authors:  Murat Uludag; Halil Unalan; Sansın Tuzun; Nese Kocabasoglu; Filiz Yıldız Aydin; Deniz Palamar; Samuray Ozdemir; Ulku Akarirmak
Journal:  Rheumatol Int       Date:  2011-11-10       Impact factor: 2.631

2.  Clinical characteristics of essential tremor in Mersin, Turkey--a population-based door-to-door study.

Authors:  Okan Dogu; Elan D Louis; Serhan Sevim; Hakan Kaleagasi; Mihriban Aral
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

3.  Regional brain metabolic correlates of self-reported depression severity contrasted with clinician ratings.

Authors:  Matthew S Milak; John Keilp; Ramin V Parsey; Maria A Oquendo; Kevin M Malone; J John Mann
Journal:  J Affect Disord       Date:  2010-04-09       Impact factor: 4.839

4.  Psychological Symptoms in Obesity and Related Factors.

Authors:  Taner Değirmenci; Nalan Kalkan-Oğuzhanoğlu; Gülfizar Sözeri-Varma; Osman Özdel; Semin Fenkçi
Journal:  Noro Psikiyatr Ars       Date:  2015-03-01       Impact factor: 1.339

5.  Cognitive Functioning in Euthymic Bipolar Patients on Monotherapy with Novel Antipsychotics or Mood Stabilizers.

Authors:  Vesile Şentürk Cankorur; Hilal Demirel; Cem Atbaşoğlu
Journal:  Noro Psikiyatr Ars       Date:  2016-09-01       Impact factor: 1.339

Review 6.  Measuring depression and PTSD after trauma: common scales and checklists.

Authors:  Jennifer L Steel; Andrea C Dunlavy; Jessica Stillman; Hans Christoph Pape
Journal:  Injury       Date:  2011-01-08       Impact factor: 2.586

7.  Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey.

Authors:  S Sevim; O Dogu; H Kaleagasi; M Aral; O Metin; H Camdeviren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

8.  Cross-Cultural Psychometric Properties of the Hamilton Depression Rating Scale.

Authors:  Erik Vindbjerg; Guido Makransky; Erik Lykke Mortensen; Jessica Carlsson
Journal:  Can J Psychiatry       Date:  2018-05-02       Impact factor: 4.356

9.  Sertraline in the treatment of depressive disorders in patients with Parkinson's disease.

Authors:  Silvia Marino; Edoardo Sessa; Giuseppe Di Lorenzo; Giuseppina Digangi; Antonella Alagna; Placido Bramanti; Paolo Di Bella
Journal:  Neurol Sci       Date:  2008-11-11       Impact factor: 3.307

10.  Relationship of Apathy with Depressive Symptom Severity and Cognitive Functions in Geriatric Depression.

Authors:  Gülfizar Sözeri-Varma; Ceren Bingöl; Osman Zülkif Topak; Yaşar Enli; Osman Özdel
Journal:  Noro Psikiyatr Ars       Date:  2019-05-06       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.